Anti-ccr8 agents
AssigneeMemorial Sloan Kettering Cancer Center
InventorsAlexander Y. Rudensky, George Plitas, Laura M. Walker, Noel Pauli, Robert Pejchal, Cory Ahonen
Life of this patent
Estimating the term…
Abstract
The present invention provides, among other things, methods and compositions for diagnosing and/or treating cancer by targeting CCR8. In particular, the present invention provides technologies for depleting Treg cells, and particularly tumor-infiltrating Treg cells.
Claims32
An antibody agent that is or comprises an antibody or antigen binding fragment thereof, which comprises a heavy chain variable domain and a light chain variable domain,
- wherein the heavy chain variable domain has an amino acid sequence as set forth in one of:
- a)
- Xn1 FTFSSYGMH Xn2 VISYDGSNKYY AFSVKG Xn3 ARVRRIAGRAGYGMDV Xn4
- b)
- Xn1 YSISSGYYWG Xn2 SIYHSGNTYYRPSLKS Xn3 ARGKGGSWTAFGP Xn4
- c)
- Xn1 GSISSSSY AWG Xn2 SIYYTGSTYYNPSLKS Xn3 LRGHRRDYIAFDI Xn4
- d)
- Xn1 GSISSSSY AWG Xn2 SIYYTGSTYYNPSLKS Xn3 VRGHRRDYIAFDI Xn4
- e)
- Xn1 FTFNAYAMN Xn2 RIRSKSNNY ATYYADSVKD Xn3 VRQSYGNSNY
- AMDY Xn4
- f)
- Xn1 FTFNAY AMN Xn2 RIRSKSNNY A TYY AASVKD Xn3 VRQSYGNSNY
- AMDY Xn4;
- and
- wherein the light chain variable domain has an amino acid sequence as set forth in one of:
- a)
- Xn1 RASQSINSYLN Xn2 AASSLQS Xn3 QESYSTPIT Xn4
- b)
- Xn1 RASQSISSFLN Xn2 AASSLQS Xn3 QQGHSTPPT Xn4
- c)
- Xn1 RASQSISSYLN Xn2 AASSLQS Xn3 QQSHNLPT Xn4
- d)
- Xn1 RASQSISSYLN Xn2 AASSLQS Xn3 QQSHNLPT Xn4
- e)
- Xn1 RSSKSLLHSNGNTYL Y Xn2 RMSNLAS Xn3 MQHLEYPFT
- Xn4
- f)
- Xn1 RSSKSLLHSNGNTYL Y Xn2 RKSNLAS Xn3 MQHLEYPFT
- Xn4;
- wherein each X, independently, is an amino acid, and each of n1;
- n2;
- n3;
- and n4, independently, is O to about 40.
An antibody agent that is or comprises an antibody or antigen binding fragment thereof, which antibody agent comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain has an amino acid sequence including each of:
- a sequence selected from SEQ ID Nos. 6-9;
- a sequence selected from SEQ ID Nos. 10-14;
- a sequence selected from SEQ ID Nos. 1-5;
- and
- wherein the light chain variable domain has an amino acid sequence including each of:
- a sequence selected from SEQ ID Nos. 15-18;
- a sequence selected from SEQ ID Nos. 19-21;
- and a sequence selected from SEQ ID Nos. 22-25.
-11. (canceled)
An antibody agent whose heavy chain variable domain amino acid sequence comprises or consists of a sequence substantially identical to a sequence selected from SEQ ID Nos. 38-43 and whose light chain variable domain amino acid sequence comprises or consists of a sequence substantially identical to a sequence selected from SEQ ID Nos. 44-49.
(canceled)
(canceled)
(canceled)
(canceled)
-29. (canceled)
(canceled)
-37. (canceled)
A method of characterizing an antibody agent, the method comprising:
- a) providing an antibody agent to be characterized that comprises an antibody whose heavy chain variable domain amino acid comprises or consists of a sequence substantially identical to one SEQ ID Nos. 38-43 and/or whose light chain variable domain sequence comprises or consists of a sequence substantially identical to one of SEQ ID Nos. 44-49, or an antigen-binding element thereof;
- b) determining for the antibody agent one or more of:
- i. human CCR8 binding
- ii. cynomolgus monkey CCR8 binding
- iii. antagonism of CCLI signaling
- iv. antagonism of MCV148 signaling
- v. induction of ADCC,
- relative to that observed for a reference antibody whose heavy chain variable domain amino acid sequence is selected from the group consisting of SED ID Nos 38-43 and whose light chain variable domain amino acid sequence is selected from the group consisting of SEQ ID Nos 44-49, so that the provided antibody agent is characterized.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.